Sanofi-Aventis Scans Asian Firms For Alliances In Biosimilar Development And Marketing
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - European drug maker Sanofi-Aventis is scouting for Asia-centric joint ventures or collaborative arrangements to accelerate its presence in the biosimilars space. Sanofi is hoping to make up ground as some of its global peers have advanced in the segment to capitalize on some of the biggest revenue drivers expected to unfold in the next five to eight years
You may also be interested in...
Biosimilars Opportunity In China, But Regulatory Pathway Still Missing - Biosimilars Asia Conference
SHANGHAI - Biosimilars makers foresee a huge opportunity in the emerging pharma market of China, which is expected to grow by 22-25% as of 2014, speakers from the IBC Biosimilars Asia Conference in Shanghai said May 24
Biosimilars Opportunity In China, But Regulatory Pathway Still Missing - Biosimilars Asia Conference
SHANGHAI - Biosimilars makers foresee a huge opportunity in the emerging pharma market of China, which is expected to grow by 22-25% as of 2014, speakers from the IBC Biosimilars Asia Conference in Shanghai said May 24
Nichi-Iko Takes Share Of Korean Biosimilar Firm, Gains Japanese Rights For Remicade And Herceptin Generics
TOKYO - Nichi-Iko has upped its capability to bring biosimilars to the Japanese market, buying a 33 percent stake in South Korean biosimilar firm Aprogen, giving the Japanese generics maker exclusive rights to Aprogen products in Japan